EpiPen

Mylan Settles Charges With SEC
Risk & Compliance

Mylan Settles Charges With SEC

Regulators said the pharmaceutical company failed to make disclosures around the DOJ’s investigation of its EpiPen.
By Lauren Muskett | September 27, 2019
Read More
Pfizer and Mylan to Combine Off-Patent Drugs Businesses
M&A

Pfizer and Mylan to Combine Off-Patent Drugs Businesses

The combined company, which will sell Mylan’s EpiPen and Pfizer’s Viagra, could draw annual sales of more than $20 billion.
By Lauren Muskett | July 29, 2019
Read More
Mylan Underpaid U.S. on Rebates for EpiPen
Risk & Compliance

Mylan Underpaid U.S. on Rebates for EpiPen

A federal official says the drugmaker misclassified EpiPen, possibly costing Medicaid millions of dollars in rebates.
By Matthew Heller | October 6, 2016
Read More
Mylan to Pay 92% Premium for Sweden’s Meda
Risk

Mylan to Pay 92% Premium for Sweden’s Meda

After a relentless pursuit, pharmaceutical firm Mylan pays a large premium to acquire a company that sells over-the-counter drugs.
By Matthew Heller | February 11, 2016
Read More